Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American ...

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...

Google Photos allows you to store and organize your photos and videos seamlessly online. While the service is highly efficient for storage, there might be times when you need to download all your ...

Three years ago, Google Photos’ free unlimited uploads came to an end, marking a significant shift for many users. For me, this transition was less dramatic than it might have been, as I had ...

Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which ...

"This process begins by removing unsafe, violent, or low-quality images," the paper reads. " We then eliminate AI-generated images to prevent the model from learning artifacts or biases commonly ...

Natco Pharma has submitted to the U.S. Food and Drug Administration an abbreviated new drug application for a generic version of Novartis’ cancer drug Tabrecta (capmatinib hydrochloride).

The trial compared the efficacy of Novartis’ Leqvio as a single agent against ezetimibe and a placebo. Credit: VILTVART/Shutterstock. Novartis has revealed that its Phase III V-MONO clinical trial of ...

Traditional methods of making VD3 rely on large, inefficient reactors. However, the new microfluidic approach solves these problems by allowing for continuous production with a much-improved yield ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...